All In Biotech

Drug Trial Radar · NCT05249920

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)

Last checked: Nov 20, 2026Latest source record: Aug 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,362

Actual

Start

Mar 18, 2022

Primary completion

Feb 17, 2023

Study completion May 19, 2023

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicentre, randomized, double-blind, placebo parallel controlled, investigator-sponsored study that aims to investigate the efficacy and safety of Edaravone Dexborneol treatment in patients with acute ischemic stroke who had received early reperfusion therapy.

Conditions

  • Acute Ischemic Stroke
  • Mechanical Thrombectomy
  • Edaravone Dexborneol
  • Phase III

Interventions

  • Edaravone Dexborneol Concentrated Solution for injectionDrug

    Edaravone and Dexborneol Concentrated Solution for Injection, 15 ml (37.5 mg, containing edaravone 30 mg and dexborneol 7.5 mg) in 3 ampoule bottles, twice a day for 10 to 14 days.

  • Edaravone Dexborneol placeboDrug

    Edaravone and Dexborneol placebo, 15 ml in 3 ampoule bottles, twice a day for 10 to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Favorable functional outcomeTime frame: at 90 days after randomization
  2. Incidence of severe adverse event (Safety outcome)Time frame: at 90 days after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.